Table 2.
Results of the meta-analyses of intensive glycaemic control
| Boussageon6 | Hemmingsen7 | |
|---|---|---|
| Trials, N | 13 | 20 |
| Patients, N | 34 533 | 29 486 |
| Δ HbA1c (%) | 0.80 | – |
| Confidence interval | 99% | 95% |
| Overall mortality | RR (99% CI) | RR (95% CI) |
| 1.04 (0.91 to 1.19) | 1.01 (0.90 to 1.13) | |
| CV mortality | 1.11 (0.86 to 1.43) | 1.06 (0.90 to 1.26) |
| Non-fatal MIa | 0.85 (0.74 to 0.96) | 0.87 (0.76 to 1.00) |
| Stroke | 0.96 (0.83 to 1.13) | 0.96 (0.80 to 1.16) |
| Congestive heart failure | 1.17 (0.91 to 1.50) | NR |
| Nephropathy | 0.90 (0.85 to 0.96)b | 0.83 (0.64 to 1.06) |
| Retinopathy | 0.85 (0.71 to 1.03) | 0.80 (0.67 to 0.94)c |
| Neuropathy | 0.99 (0.95 to 1.03) | NR |
| Severe hypoglycaemia | 2.33 (1.62 to 3.36) | 2.05 (1.39 to 2.02) |
a
Secondary endpoint.
b
Albuminuria.
c
Composite endpoint. CV = cardiovascular mortality. MI = myocardial infarction. NR = not reported. RR = relative risk. Bold = significant.